# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Naz Rahman upgrades Virpax Pharmaceuticals (NASDAQ:VRPX) from Hold to Buy and announces $3 price target.
Cannabis ancillary company EnWave Corporation (TSX-V: ENW) (FSE: E4U) announced on Thursday that it had tapped Danna Dunnage as...